Last reviewed · How we verify
Peripheral Nerve Block
Peripheral Nerve Block, marketed by Geisinger Clinic, holds a position in the pain management segment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its patent. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Peripheral Nerve Block |
|---|---|
| Also known as | marcaine, bupivicaine |
| Sponsor | Geisinger Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial (NA)
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- The Effects of Various Concentrations of Ropivacaine on the Onset and Duration of Ankle Blocks (NA)
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population (PHASE2)
- Platelet Rich Plasma Injections In Young And Old Human Subjects (PHASE2)
- Effectiveness of Thoracoabdominal Nerve Block (M-TAPA) on Postoperative Pain Relief in Laparoscopic Hysterectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |